Welcome to our dedicated page for Cytomx Therapeutics news (Ticker: CTMX), a resource for investors and traders seeking the latest updates and insights on Cytomx Therapeutics stock.
The CTMX news page on Stock Titan aggregates recent coverage and official announcements related to CytomX Therapeutics, Inc., a clinical-stage, oncology-focused biopharmaceutical company listed on the Nasdaq Global Select Market. CytomX reports that it is developing novel, conditionally activated, masked biologics based on its PROBODY® therapeutic platform, with a focus on cancer indications such as advanced colorectal cancer and advanced melanoma.
Visitors to this page can review news items that describe the progress of CytomX’s clinical programs, including updates on varsetatug masetecan (Varseta-M, formerly CX-2051), a masked EpCAM-directed antibody-drug conjugate with a topoisomerase-1 inhibitor payload, and CX-801, a masked interferon alpha-2b PROBODY® cytokine. Company press releases have discussed Phase 1 dose escalation and expansion activities, translational biomarker data, and plans for potential later-stage development in colorectal cancer and melanoma.
In addition to pipeline updates, CytomX news often includes financial results, business updates, and information about investor conference presentations. These items provide context on the company’s operating priorities, cash position, and interactions with the investment community. News releases also highlight research and collaboration activities involving its PROBODY® platform, such as work on T-cell engagers and cytokine-based approaches in partnership with other biopharmaceutical companies.
By following CTMX news, investors and researchers can monitor how CytomX describes the evolution of its PROBODY® technology, its clinical data disclosures, and its collaborations with partners including Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna. This page offers a centralized view of publicly released information that may be relevant to understanding the company’s development-stage oncology pipeline and corporate activities.
CytomX Therapeutics, Inc. (Nasdaq: CTMX) reported its third quarter 2020 financial results, showing revenue of $17.8 million, a 66% increase from the same period in 2019. The company highlighted advancements in its clinical pipeline, including five Probody programs in the clinic, with four in Phase 2 studies. CX-2009 and CX-2029 are among the candidates being developed with initial data anticipated in late 2021. As of September 30, CytomX had $321.1 million in cash and equivalents, reflecting strong financial health.
CytomX Therapeutics (Nasdaq: CTMX) announced the initiation of a Phase 2 expansion study for CX-2029, a Probody drug conjugate targeting CD71, an important cancer target. This study will include various cancer types and is expected to enroll around 25 patients per cohort, focusing on overall response rate (ORR) and safety. The collaboration with AbbVie allows CytomX to earn up to $390 million in milestone payments. Initial data from the study is anticipated in late 2021, further showcasing CytomX's innovative approach to oncology.
CytomX Therapeutics (Nasdaq: CTMX) will announce its second quarter 2020 financial results on November 5, 2020, after U.S. market close. A teleconference will be held at 5:00 p.m. ET with a live audio webcast available on its website. CytomX focuses on developing investigational antibody therapeutics through its Probody technology, which aims to improve the efficacy and safety of cancer treatments. The company has established collaborations with major pharmaceutical entities to develop a pipeline of innovative therapeutics targeting difficult cancers.
CytomX Therapeutics (NASDAQ:CTMX) announces the retirement of W. Michael Kavanaugh, M.D., its Chief Scientific Officer, effective December 1, 2020. He will continue as an advisor on the Scientific Advisory Board. Marcia P. Belvin, Ph.D., is promoted to Senior Vice President, Head of Research, bringing nearly 20 years of oncology experience. CytomX focuses on developing Probody therapeutics, which selectively target tumors while minimizing toxicity to healthy tissues. The company's pipeline includes innovative candidates like CX-2009 and CX-2029, aimed at previously undruggable cancer targets.
CytomX Therapeutics (NASDAQ: CTMX) announced the granting of stock options to nine new employees on September 15, 2020. A total of 211,000 shares were issued at an exercise price of $7.22, equal to the closing price on that date. This action is part of the Company's 2019 Employment Inducement Incentive Plan, aimed at attracting talent. CytomX is a clinical-stage biopharmaceutical company focused on oncology, utilizing its Probody technology to develop innovative cancer treatments, partnering with major industry players like AbbVie and Bristol Myers Squibb.
CytomX Therapeutics (Nasdaq: CTMX) announced that CEO Sean McCarthy will participate in two virtual healthcare conferences in September 2020. The events are the Citi’s 15th Annual BioPharma Virtual Conference on September 10, 2020, and the H.C. Wainwright 22nd Annual Global Investment Conference on September 15, 2020, at 12:00 p.m. ET. A live audio webcast of the latter will be available on CytomX's website, with a 90-day archive. CytomX is pioneering a novel class of antibody therapeutics for cancer treatment, collaborating with major biotech firms to develop innovative therapies.
CytomX Therapeutics (CTMX) announced its second-quarter 2020 financial results, reporting revenue of $16.6 million, up from $9.0 million in Q2 2019. The increase is attributed to revenue from collaborations, including an $80 million upfront payment from Astellas. Cash and equivalents rose to $346.4 million as of June 30, 2020. The company is advancing its clinical pipeline, which includes notable drug candidates like CX-2029 and CX-2009, with plans for Phase 2 cohorts later this year despite COVID-19 challenges. R&D expenses decreased by $6.8 million year-over-year, showcasing effective cost management.
CytomX Therapeutics (Nasdaq: CTMX) announced that Dr. Sean McCarthy, CEO, will present at the 2020 Wedbush PacGrow Virtual Healthcare Conference on August 12, 2020, at 1:10 p.m. ET. The presentation will provide a corporate update and will be available via live audio webcast on the company’s website. CytomX focuses on developing Probody therapeutics designed to selectively target tumors while sparing healthy tissue, aiming to create safer cancer treatments. The company has partnerships with major firms, including AbbVie and Bristol Myers Squibb.
CytomX Therapeutics (CTMX) announced that partner Bristol Myers Squibb presented preclinical data on anti-CTLA-4 Probody therapeutics, BMS-986249 and BMS-986288, at the AACR 2020 Virtual Annual Meeting II. These therapeutics aim to enhance treatment for metastatic melanoma and advanced solid tumors. BMS-986249 is co-administered with Opdivo, while BMS-986288 is under trial for advanced tumors as monotherapy and with nivolumab. Both programs stem from a 2014 collaboration agreement, showcasing the potential of CytomX’s Probody technology in oncology.
CytomX Therapeutics, Inc. (Nasdaq: CTMX) has announced that its CEO, Sean McCarthy, will participate in two virtual healthcare conferences in June 2020. The first event is the Jefferies Virtual Healthcare Conference, where he will present a Corporate Update on June 3 at 11:30 a.m. ET. The second is the Goldman Sachs 41st Annual Global Healthcare Conference on June 10 at 4:40 p.m. ET, where he will engage in a Fireside Chat. Live audio webcasts will be accessible on CytomX's website, with archived replays available for 90 days.